Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia

Atherosclerosis

Volumn 122, Issue 2, 1996, Pages 225-233

  Tsuda, Yoshiyasu ^a   Satoh, Kiyoto ^a   Kitadai, Masaya ^a   Takahashi, Tsutomu ^a   Izumi, Yoshinari ^a   Hosomi, Naohisa ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Fibrinogen; Hyperlipoproteinemia, type II; Pravastatin sodium; Simvastatin

Indexed keywords

ALBUMIN; CHOLESTEROL; FIBRINOGEN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029890780     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05757-9     Document Type: Article

References (19)

1. Grotta JC, Yatsu FM, Pettigrew LC, Rhodes H, Bratina P, Vital D, Alam R, Earls R, Picone C. Prediction of carotid stenosis progression by lipid and hematologic measurements. Neurology 1989;39:1325-1331.
2. Wilhelmsen L, Svardsudd K, Bengtsen KK, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med 1984;311:501-505.
3. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. J Am Med Assoc 1987;258:1183-1186.
4. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. Br Med J 1991;303:605-609.
5. Fisher M, Meiselman HJ. Hemorheological factors in cerebral ischemia. Stroke 1991;22:1164-1169.
6. Leonhardt H, Arntz H-R, Klemens UH. Studies of plasma viscosity in primary hyperlipoproteinaemia. Atherosclerosis 1977;28:29-40.
7. Lowe GDO, Drummond MM, Third JLHC, Bremner WF, Forbes CD, Prentice CRM, Lawrie TDV. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinemia. Thromb Haemost 1980;42:1503-1507.
8. Arntz HR, Leonhardt H, Dreykluft H-R. Influence of clofibrate on blood viscosity in primary hyperlipoproteinemia. Klin Wochenschr 1979;57:43-47.
9. Rillaerts EG, Engelmann GJ, Van Camp KM, De Leeuw I. Effect of omega-3 fatty acids in diet of type I diabetic subjects on lipid values and hemorheological parameters. Diabetes 1989;38:1412-1416.
10. Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 1990;85:249-256.
11. Avellone G, Di Garbo V, Cordova R, Reneli G, De Simone R, Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia. Curr Ther Res 1994;55:1335-1344.
12. Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 1990;83:53-58.
13. Koenig W, Hehr R, Ditschuneit HH, Kuhn K, Ernst E, Rosenthal J, Hombach V. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein (a)? J Clin Pharmacol 1992;32:539-545.
14. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991;31:512-517.
15. Nicolaides AN, Bowers R, Horbourne T, Kidner PH, Besterman EM. Blood viscosity, red cell flexibility, haematocrit, and plasma-fibrinogen in patients with angina. Lancet 1977;ii:943-945.
16. Scott WA. Hydrophilicity and differential pharmacology of pravastatin. In: Lipid Management. Pravastatin and the Differential Pharmacology of HMG-CoA Reductase Inhibitors. Royal Soc Med Services. Round Table Series 1989;16:17-25.
17. Pan HY, Funke PT, Willard DA, Mckinstry DN. Pharmacokinetics, pharmacodynamics and safety of pravastatin sodium, a potent inhibitor of HMG-CoA reductase, in healthy volunteers. In: New Advances in the Control of Lipid Metabolism. Focus on Pravastatin. Royal Soc Med Services. International Congress and Symposium Series 1989;162:9-21.
18. Duggan DE, Chen I-W, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S. The physiological disposition of lovastatin. Drug Metab Dispos 1988;17:166-173.
19. Vickers S, Duncan CA, Chen I-W, Rosengay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138-145.